Contract 36F79721D0086

Amgen USA Inc · Department Of Veterans Affairs · September 21, 2021

Fixed Price With Economic Price AdjustmentFull & Open CompetitionNAICS 325412

Amgen USA Inc was awarded a federal contract by Department Of Veterans Affairs on September 21, 2021 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 18 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 17, 2026. If all options are exercised, the contract could reach $3.37 billion.

Potential value
$3.37B
if all options exercised
Modifications
18
Latest March 17, 2026

Contract details

PIID
36F79721D0086
Award type
Pricing
Fixed Price With Economic Price Adjustment
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
325412 · Pharmaceutical Preparation Manufacturing
Product / service
Drugs And Biologicals
First action
September 21, 2021
Latest action
March 17, 2026

Description

TEMPORARY PRICE REDUCTION

Modification timeline

  • March 17, 2026
    Mod P00083 · Supplemental Agreement For Work Within Scope
    $0
  • March 4, 2026
    Mod P00082 · Supplemental Agreement For Work Within Scope
    NDC CHANGES
    $0
  • February 26, 2026
    Mod P00081 · Supplemental Agreement For Work Within Scope
    $0
  • February 24, 2026
    Mod P00080 · Supplemental Agreement For Work Within Scope
    NDC CHANGES
    $0
  • February 12, 2026
    Mod P00079 · Supplemental Agreement For Work Within Scope
    TEMPORARY PRICE DECREASE
    $0
  • January 28, 2026
    Mod P00078 · Supplemental Agreement For Work Within Scope
    PRODUCT ADDITIONS, DELETIONS, AND NDC CHANGES
    $0
  • January 5, 2026
    Mod P00077 · Supplemental Agreement For Work Within Scope
    NDC CHANGE
    $0
  • December 23, 2025
    Mod P00074 · Supplemental Agreement For Work Within Scope
    LIFECYCLE CHANGE TO PERMANENT FCP & TEMPORARY CONTRACT EXTENSION
    $0
  • December 23, 2025
    Mod P00076 · Supplemental Agreement For Work Within Scope
    $0
  • December 22, 2025
    Mod P00075 · Supplemental Agreement For Work Within Scope
    $0

Similar contracts

RecipientAgencyDateObligated
Petnet Solutions, Inc.Department Of Veterans AffairsApril 1, 2026$387.4K
Eli Lilly And CompanyDepartment Of Veterans AffairsApril 1, 2026$0
Exelan Pharmaceuticals IncDepartment Of Veterans AffairsApril 1, 2026$0
Cardinal Health 414, LlcDepartment Of Veterans AffairsApril 1, 2026$122.9K
Guardian Pharmacy Of Indianapolis Nuclear, LlcDepartment Of Veterans AffairsApril 1, 2026$0
Jubilant Draximage IncDepartment Of Veterans AffairsApril 1, 2026$0

Top contractors in NAICS 325412

Lifetime obligated dollars across all federal contracts in this NAICS code.

#ContractorContractsObligated
1Mckesson Corporation1,187$4.96B
2Merck Sharp & Dohme Llc26$894.71M
3Sanofi Vaccines Us Inc.57$702.38M
4Pfizer Inc169$541.15M
5Glaxosmithkline, Llc14$505.04M
6Phlow Corp.1$105.27M
7Exelan Pharmaceuticals Inc76$104.30M
8Seqirus USA Inc47$59.15M
9Emergent Biosolutions Canada Inc2$53.73M
10Mckesson Specialty Distribution Llc1$51.05M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 36F79721D0086?

Contract 36F79721D0086 is a federal contract awarded to Amgen USA Inc by Department Of Veterans Affairs on September 21, 2021 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 18 times since the base award.

Who won contract 36F79721D0086?

Amgen USA Inc won contract 36F79721D0086 from Department Of Veterans Affairs.

How much is contract 36F79721D0086 worth?

Contract 36F79721D0086 has obligated $0 to date but carries a potential ceiling of $3.37 billion if fully funded and all options are exercised.